Xtacy Therapeutics Corp.
Pegasus Mercantile Inc. is an incubator, venture capital firm specializing in incubation, startup and early stage. The firm seeks to invest in the public and private sectors that focus on preventative health, wellness issues, related consumer products, biotechnology, specific areas of pain, Psychedelic, depression, mental illness health and medicine sectors. By investing in pioneering techniques … Read more
Xtacy Therapeutics Corp. (XTCYF) - Total Assets
Latest total assets as of June 2025: $369.23K USD
Based on the latest financial reports, Xtacy Therapeutics Corp. (XTCYF) holds total assets worth $369.23K USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Xtacy Therapeutics Corp. - Total Assets Trend (2020–2024)
This chart illustrates how Xtacy Therapeutics Corp.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Xtacy Therapeutics Corp. - Asset Composition Analysis
Current Asset Composition (September 2024)
Xtacy Therapeutics Corp.'s total assets of $369.23K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Xtacy Therapeutics Corp.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Xtacy Therapeutics Corp.'s current assets represent 100.0% of total assets in 2024, unchanged from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 100.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Xtacy Therapeutics Corp. Competitors by Total Assets
Key competitors of Xtacy Therapeutics Corp. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pappajack Bhd
KLSE:0242
|
Malaysia | RM361.68 Million |
|
Evergreen Max Cash Capital Berhad
KLSE:0286
|
Malaysia | RM361.11 Million |
|
Samsung Card Co. Ltd.
KO:029780
|
Korea | ₩32.17 Trillion |
|
Yiren Digital Ltd
F:19YA
|
Germany | €14.45 Billion |
|
Yixin Group Limited
F:1YX
|
Germany | €50.34 Billion |
|
BFF Bank S.p.A
F:2BF
|
Germany | €12.13 Billion |
|
Resurs Holding AB (publ)
F:4R6
|
Germany | €50.33 Billion |
|
Aeon Credit Service Bhd
KLSE:5139
|
Malaysia | RM15.62 Billion |
Xtacy Therapeutics Corp. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Xtacy Therapeutics Corp. generates 0.14x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Xtacy Therapeutics Corp. is currently not profitable relative to its asset base.
Xtacy Therapeutics Corp. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.51 | 0.14 | 0.41 |
| Quick Ratio | 0.51 | 0.14 | 0.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-349.69K | $ -591.04K | $ -423.29K |
Xtacy Therapeutics Corp. - Advanced Valuation Insights
This section examines the relationship between Xtacy Therapeutics Corp.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.76 |
| Latest Market Cap to Assets Ratio | 0.62 |
| Asset Growth Rate (YoY) | 0.6% |
| Total Assets | $433.91K |
| Market Capitalization | $267.38K USD |
Valuation Analysis
Below Book Valuation: The market values Xtacy Therapeutics Corp.'s assets below their book value (0.62 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Xtacy Therapeutics Corp.'s assets grew by 0.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Xtacy Therapeutics Corp. (2020–2024)
The table below shows the annual total assets of Xtacy Therapeutics Corp. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-09-30 | $433.91K | +0.57% |
| 2023-09-30 | $431.46K | +44.87% |
| 2022-09-30 | $297.83K | +1062.13% |
| 2021-09-30 | $25.63K | +540.86% |
| 2020-09-30 | $4.00K | -- |